Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy
- 18 February 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 145 (6), 1713-1715
- https://doi.org/10.1016/j.jaci.2020.02.002
Abstract
No abstract availableFunding Information
- GlaxoSmithKline (208115, MEA115588, 200862)
- GlaxoSmithKline
This publication has 7 references indexed in Scilit:
- Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthmaEuropean Respiratory Journal, 2018
- Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trialJournal of Allergy and Clinical Immunology, 2017
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialThe Lancet Respiratory Medicine, 2017
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Reslizumab for Poorly Controlled, Eosinophilic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthmaJournal of Allergy and Clinical Immunology, 2010
- Psychometric validity of the 22‐item Sinonasal Outcome TestClinical Otolaryngology, 2009